The IDKmonitor® Adalimumab Free ADA ELISA is for the detection of free anti-drug antibodies against Adalimumab (e.g., HUMIRA®) and measures free anti-Adalimumab antibodies in EDTA plasma and serum.

Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, rheumatoid arthritis, or psoriasis are often treated with anti-TNFa antibodies, which directly target the underlying inflammatory processes.

The clinical efficacy of an anti-TNFa therapy correlates with the trough level of the therapeutic antibody, the drug level just before the next application of the anti-TNFa antibody. Several factors influence the trough level, among them dosage and frequency of anti-TNFa blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation anti-drug antibodies, ADA). It is thought that ADA functionally neutralizes the therapeutic antibodies or induces their rapid elimination. Consequences of ADA formation can be therapy failure and allergic reactions during anti-TNFa antibody application.

In combination with the drug level determination of Adalimumab, the IDKmonitor® Adalimumab Free ADA ELISA is an opportunity for treating physicians to monitor and optimize therapy early on.

The IDKmonitor® Adalimumab Free ADA ELISA is Health Canada Licensed.

Browse our other IDKmonitor® Adalimumab ELISAs.